New Treatment for Retinal Diseases

Dear Colleagues,

Blinding retinal diseases are a major, and rapidly growing, public health problem around the world.  Although great strides have been made in our understanding of these diseases, we still lack effective treatments for many of them.  While we have treatments that block the end stage of Macular Degeneration, these do not stop the progressive retinal degeneration that leads to blindness.  Similarly, we have interventions that blunt the effects of end stage neovascularization in diabetic retinopathy, but no treatments that can prevent the early stages of the disease. Increased intraocular pressure leading to glaucoma can be treated surgically or with drugs, but many glaucoma patients have little or no increase in intraocular pressure, and there are currently no options for these patients.  Other blinding conditions, though less prevalent, are also in need of new treatments.

Fortunately, there are hopeful signs of new therapies for these and related diseases. The goal of this special issue is to highlight new and emerging therapies that have the potential to revolutionize treatment of degenerative retina disease.  From gene therapy to epigenetic modifiers to small molecule anti-oxidants to innovative drug delivery methods, all of these offer hope to millions of patients. With both review articles and original research papers we will explore the potential and the pitfalls of new treatments currently under development.

Prof. Dr. Colin J. Barnstable
Prof. Dr. Joyce Tombran-Tink
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gene therapy
• exosomes
• drug delivery
• nanoparticles
• epigentic modifiers